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Abstract
Background: Immune restoration disease (IRD) is an adverse consequence of antiretroviral
therapy, where the restored pathogen-specific response causes immunopathology. Mycobacteria
are the pathogens that most frequently provoke IRD and mycobacterial IRD is a common cause of
morbidity in HIV-infected patients co-infected with mycobacteria. We hypothesised that the
excessive effector immune response in mycobacterial IRD reflects impaired regulation by IL-10.
Results: We studied two patients who experienced mycobacterial IRD during ART. One patient
developed a second episode of IRD with distinct clinical characteristics. Findings were compared
with patients 'at risk' of developing IRD who had uneventful immune recovery. Peripheral blood
mononuclear cells (PBMC) from all subjects were stimulated with mycobacterial antigens in the
form of purified protein derivative (PPD). Supernatants were assayed for IFN? and IL-10. In
response to PPD, PBMC from IRD patients generated IFN? during the first IRD episode, whilst cells
from non-IRD controls produced more IL-10.
Conclusion: We present preliminary data from two HIV-infected patients showing an imbalance
between IFN? and IL-10 responses to mycobacterial antigens during mycobacterial IRD. Our
findings suggest that imbalanced effector and regulatory cytokine responses should be investigated
as a cause of IRD.
Background
Immune restoration disease (IRD) after commencing
antiretroviral therapy (ART) is considered to be a conse-
quence of restoring an immune response against an active
(often quiescent) infection by an opportunistic pathogen,
or antigens of non-viable pathogens, that results in immu-
nopathology [1,2]. Mycobacterium tuberculosis (Mtb) and
non-tuberculous mycobacteria are pathogens that com-
monly provoke IRD [3,4]. Patients experiencing mycobac-
terial IRD often present with fever and lymphadenitis, but
may also have pulmonary infiltrates or inflammatory
masses. A cutaneous delayed-type hypersensitivity (DTH)
response to mycobacterial antigens is a characteristic find-
ing [1,5,6], and coincides with excessive production of
Type 1 (Th1) cytokines [7], probably by memory CD4+ T
cells. However, the immunopathogenesis of mycobacte-
rial IRD is not fully understood and may be variable since
the clinical presentations can be diverse. Tissue inflamma-
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tion presenting during the first few months of ART usually
has the features of a DTH immune response [2], but some
patients present with suppurating lymphadenitis and/or
disease that presents later [8-10].
Immunity to mycobacterial infections is influenced by the
counteracting effects of effector cytokines and regulatory
cytokines, such as interleukin (IL)-10, in patients with and
without HIV infection [11-14]. As IL-10 provides a regula-
tory mechanism for Th1 memory CD4+ T cell responses
[15,16], we hypothesised that the excessive effector
response in mycobacterial IRD reflects impaired regula-
tion by IL-10. We present preliminary data from two HIV-
infected patients showing an imbalance between inter-
feron-gamma (IFN?) and IL-10 responses to mycobacte-
rial antigens during mycobacterial IRD.
Results
Subjects
Patient 1 (P1) was a 48-year-old Caucasian male who
developed Mycobacterium celatum IRD one month after
commencing ART. This case has been described previously
[17]. Briefly, he presented with a CD4+ T cell count of 48/
µL and plasma HIV RNA level >100,000 copies/mL. He
developed fever on day 11 of ART and sputum collected
on each of the following 3 days yielded M. celatum. Chest
radiography and a computer tomography (CT) scan
revealed areas of consolidation in both lungs. On day 27
of ART his CD4+ T cell count had increased to 189/µL, his
plasma HIV RNA level had decreased to 933 cells/µL and
DTH skin testing demonstrated an 18 mm response to
purified protein derivative (PPD) and a 10 mm response
to Mycobacterium avium antigen. Prednisone was adminis-
tered and the patient's symptoms resolved completely.
Patient 2 (P2) was a 51-year-old Caucasian male who pre-
sented with a CD4+ T cell count of 16/µL and plasma HIV
RNA level of 54,954 copies/mL. Two routine blood cul-
tures taken at initial presentation grew Mycobacterium
avium complex (MAC). He was treated with ethambutol,
rifabutin and azithromycin. DTH skin tests with M. avium
antigen and PPD both gave reactions of 0 mm, demon-
strating anergy towards mycobacterial antigens.
Six weeks after initial presentation, he commenced ART
consisting of efavirenz, zidovudine and lamivudine. Four
months later, he was seen for a routine assessment and
had no specific complaints. However, a right axillary
lymph node was detected and the liver was palpable.
Blood tests revealed a haemoglobin level of 99 g/L, serum
CRP level of 51 mg/L and ESR of 100 mm/hr but normal
LDH and liver function tests. His CD4+ T cell count was
42/µL and plasma HIV RNA level <50 copies/mL. An aspi-
rate of the right axillary lymph node and a sputum sample
both grew MAC. Blood cultures were negative. A chest CT
scan revealed marked axillary and mediastinal lymphade-
nopathy. On this occasion, DTH skin testing gave reac-
tions of 18 mm to M. avium antigen and 17 mm to PPD.
He continued on anti-MAC antibiotics and commenced
prednisolone therapy for likely MAC IRD. After 4 weeks
the lymphadenopathy was resolving and CRP was nor-
mal. Plasma HIV RNA remained undetectable.
He had an uneventful course for 6 months until he repre-
sented unwell with 10 kg weight loss and night sweats.
There was a 5 × 6 cm draining lymph node in the cervical
region and a chronic discharging sinus in the right axilla.
No other lymphadenopathy or organomegaly was palpa-
ble. Plasma HIV RNA was still undetectable; however the
CD4+ T cell count was only 42/µL. A surgically resected
lymph node revealed the presence of mycobacteria, but
these could not be cultured. A granulomatous inflamma-
tory response with necrosis, neutrophils and karryorhectic
debris (dead neutrophils) at the centre of necrotic areas
was also demonstrated. Tests for Mtb DNA in the lymph
node, blood cultures for mycobacterial infection and a
whole blood IFN-? release assay with Mtb-specific anti-
gens (QuantiFERON-TB Gold, Cellestis) were all negative.
The serum CRP level was normal. DTH skin testing
revealed an absent response to M. avium antigen and only
a 7 mm reaction to PPD. He continued anti-MAC antibi-
otics and recommenced prednisolone therapy.
Cytokine production
To examine the production of effector and regulatory
cytokines, peripheral blood mononuclear cells (PBMC)
from both IRD patients and from six non-IRD patients
were cultured with antigens and a mitogen control and
supernatants assayed for IFN? and IL-10. During the first
episodes of IRD, PBMC from P1 and P2 produced more
IFN? than IL-10 in response to PPD (Figure 1). P1 retained
higher IFN? production 12 months later. Undetectable
levels of IL-10 from P2 were confirmed in a second culture
over 72 hours (Figure 2). In contrast, PBMC from 5 of the
6 non-IRD patients produced more IL-10 than IFN? after
6 months of ART (Figure 1). P3 had a history of treated
tuberculosis many years earlier and was the only non-IRD
patient to exhibit higher production of IFN? than IL-10.
P1 experienced disseminated CMV disease prior to ART.
To demonstrate that high levels of PPD-induced IFN? pro-
duction during his IRD was specific for the provoking
pathogen, his PBMC were stimulated with CMV antigen.
At the time of IRD, IFN? was undetectable (<15 pg/mL) in
the supernatants of CMV-stimulated cultures.
The second episode of IRD in P2 had different immuno-
logical characteristics to the first episode. IFN? was not
detected in supernatants of PBMC stimulated with PPD
(Figure 1). However, IL-10 was detectable after 24, 48 orAIDS Research and Therapy 2008, 5:9 http://www.aidsrestherapy.com/content/5/1/9
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72 hours stimulation (Figure 2). These IL-10 responses
remained steady after 12 months on ART.
Discussion
We present clinical and laboratory data from two patients
with mycobacterial IRD, and appropriate controls, that
support our hypothesis that IRD might reflect failure to
produce sufficient IL-10 during restoration of mycobacte-
ria-specific effector CD4+ T cell responses after commenc-
ing ART. We used PPD as an antigen to investigate
pathogen-specific cytokine responses because we and oth-
ers have shown that IRD associated with infection by Mtb
and non-tuberculous mycobacteria (NTM) is associated
with increased cellular immune responses to PPD
[1,2,5,7,17]. Our controls were considered to be 'at risk' of
developing IRD because we have previously shown that
'subclinical' infection with NTM is almost inevitable when
HIV patients in our population are severely immunodefi-
cient [18].
PPD-stimulated PBMC from both IRD patients produced
less IL-10 than IFN? during the first episode of IRD. High
IFN? production has been previously demonstrated in
Mtb IRD [7]. In contrast, IL-10 production by PPD-stimu-
lated PBMC predominated in donors without IRD, sug-
gesting sufficient regulatory control. The more vigorous
IFN? response in P1 relative to P2 may reflect better
immune reconstitution as P1 experienced an approxi-
mately 4-fold increase in CD4+ T cell count after only 1
month of ART, while P2 had a persistently low CD4+ T cell
count even after 10 months of ART. However, both
patients displayed strong DTH skin test responses at the
time of IRD, indicating that restoration of cellular
immune function may not correlate with circulating CD4+
T cell counts. Higher production of IFN? relative to IL-10
in P3 may reflect Mtb-specific immunological memory as
a consequence of previous tuberculosis.
We were able to study two episodes of IRD in P2. His sec-
ond IRD episode had different immunological and clini-
cal characteristics to the first episode. A cutaneous DTH
response to M. avium antigen was absent. High IL-10 and
low IFN? production were demonstrated following PPD
stimulation of PBMC. With the clinical findings of sinus
formation from lymph nodes and predominance of neu-
trophils in the lymph node biopsy, our data suggests that
this episode did not fit the "classical" Th1 presentation of
mycobacterial IRD. Investigation of other effector T cells
might be informative, particularly Th17 cells as these cells
may promote neutrophil responses [19].
Conclusion
In conclusion, we suggest that future studies of the immu-
nopathogenesis of mycobacterial IRD should include
analyses of mycobacteria-specific effector and regulatory
cytokine responses.
Deficient IL-10 production by PBMC stimulated with PPD  from P2 during his first IRD episode Figure 2
Deficient IL-10 production by PBMC stimulated with 
PPD from P2 during his first IRD episode. IL-10 pro-
duction was assessed over 72 hours in PBMC from P2 (filled 
circles; left plot) and compared with responses of four other 
PPD-responsive individuals (open circles, two uninfected 
donors; triangles, HIV-negative patient with active tuberculo-
sis; squares, P3 after 16 months of ART; right plot). P3 had a 
history of treated tuberculosis many years earlier. mth, 
months.
 
More IFN? than IL-10 is produced during an IRD Figure 1
More IFN? than IL-10 is produced during an IRD. 
PBMC from two IRD patients (P1 and P2) and six non-IRD 
patients (P3 to P8) were stimulated with PPD for 24 hours. 
Concentrations of IFN? (white bars) and IL-10 (black bars) 
were measured in culture supernatants. Baseline refers to a 
time-point immediately prior to commencement of ART. U, 
undetectable.
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Methods
Laboratory methods and controls
PBMC were cryopreserved prior to ART (P1 only), at each
IRD episode and after 12 months on ART. Six male HIV-
infected patients who did not develop IRD after com-
mencing ART (non-IRD patients, P3 to P8) were sampled
prior to ART and approximately 6 months later. All non-
IRD patients had CD4+ T cell counts below 100/µL and
plasma HIV RNA levels >4 log10 copies/mL before ART. At
the second PBMC collection, 5 non-IRD patients had
achieved and maintained plasma HIV RNA levels of <50
copies/mL, while the remaining patient had achieved and
maintained plasma HIV RNA levels >2 logs below his
baseline level. Four non-IRD patients experienced at least
a four-fold increase in their CD4+ T cell count after 6
months of ART (total CD4+ T cell count increased to above
150/µL), while the other 2 patients increased their CD4+ T
cell counts less than three-fold (total CD4+ T cell count
remained below 100/µL). Non-IRD patient 3 (P3) had a
history of treated tuberculosis several years earlier.
PBMC were isolated by Ficoll separation of heparinised
whole blood and cryopreserved in RPMI with 10%
dimethylsulfoxide. Thawed PBMC were cultured in 10%
FCS/RPMI at 2.5 × 106 cells/mL with 10 µg/mL PPD (Stat-
ens Serum Institute) or CMV antigen (AD169 lysate), and
12.5 µg/mL phytohaemaggutinin (mitogen control) at
37°C for 24 hours. Supernatants were assayed by ELISA
for IFN? (BD Biosciences) and IL-10 (R&D Systems).
Unstimulated cells were cultured in parallel.
In a second experiment, PBMC from P2, P3, a HIV-nega-
tive patient with active tuberculosis and two uninfected
donors were cultured at 1 × 106 cells/mL with PPD over a
72-hour time-course. Both uninfected donors were
known to have PPD-specific cells detectable by ELISpot.
Supernatants were assayed for IL-10 at 24-hour intervals
by cytometric bead array (BD Biosciences).
Informed consent was obtained from all individuals and
the study was approved by the Ethics Committee of Royal
Perth Hospital.
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